Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative
09 Dicembre 2020 - 2:15PM
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, today announced the launch
of Galactosemia Together, the first and only industry-led
Galactosemia awareness and education campaign. Developed in
partnership with the Galactosemia community, this initiative aims
to address gaps in education by providing updated, reliable and
credible resources to help connect, educate and support those
families impacted by this disease.
“We are thrilled that Applied Therapeutics is
not only providing hope for a drug that could be used in the
treatment of Galactosemia, but also is committed to creating
valuable resources in the realm of disorder awareness and
education. It is vital that patients have access to educational
materials that help them understand the disorder so that they can
make informed decisions, with the help of their medical team in
regard to their care,” said Brittany Cudzilo, Outreach Coordinator,
Board of Directors for the Galactosemia Foundation. “On behalf of
the Foundation, I’d like to thank Applied Therapeutics for their
commitment to the Galactosemia community.”
“We are pleased to partner with the Galactosemia
community in this important educational endeavor,”
said Shoshana Shendelman, PhD, Founder, CEO and Chair of the
Board of Applied Therapeutics. “Applied Therapeutics is committed
to supporting the needs of Galactosemia patients and
caregivers.”
To learn more about Galactosemia Together,
please visit Galactosemia.com.
Galactosemia is a rare, slowly progressing
metabolic disease caused by a genetic inability to break down the
sugar galactose. Aldose Reductase (AR), an enzyme known to play a
role in many diseases including Galactosemia, converts galactose
into galactitol, a toxic metabolite that builds up in tissues and
organs and can cause long-term disease complications. There are
approximately 3,000 individuals with Galactosemia in the U.S. and
about 3,500 individuals in the E.U. Most patients with Galactosemia
are under the age of 40, as newborn screening was not widely
adopted until the 1980s. Galactosemia is now included as part of
routine newborn screening in all 50 U.S. states, and in many
countries in Europe.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need. The Company’s lead drug candidate, AT-007,
is a novel central nervous system penetrant aldose reductase
inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric
metabolic disease. The Company initiated a pivotal Phase 1/2
clinical trial in June 2019, read out positive top-line
biomarker data in adult Galactosemia patients in January
2020 and announced full data from the trial in April
2020. A pediatric Galactosemia study commenced in June 2020.
The Company is also developing AT-001, a novel potent ARI that is
being developed for the treatment of Diabetic Cardiomyopathy, or
DbCM, a fatal fibrosis of the heart. The Company initiated a Phase
3 registrational study in DbCM in September 2019. The
preclinical pipeline also includes AT-003, an ARI designed to cross
through the back of the eye when dosed orally, for the treatment of
diabetic retinopathy, as well as novel dual PI3k inhibitors in
preclinical development for orphan oncology indications. To learn
more, please visit www.appliedtherapeutics.com and
follow the company on Twitter @Applied_Tx.
Investors:Maeve Conneighton(212) 600-1902
orappliedtherapeutics@argotpartners.com
Media:Gleb
Sagitovmedia@appliedtherapeutics.com
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Lug 2023 a Lug 2024